基于体素回顾性剂量学评估体表面积模型预测实际给药剂量及放射性栓塞疗效的能力
本研究对35例肝细胞癌患者的42次90Y树脂微球放射性栓塞治疗进行回顾性体素剂量学分析。按体表面积模型规划注射活度,基于99mTc-大颗粒聚合白蛋白SPECT和90Y微球PET计算肿瘤吸收剂量与剂量体积直方图。26次治疗可评估6个月疗效,客观缓解14次、无缓解12次,客观缓解者的平均剂量及剂量体积直方图指标显著高于无缓解者。
要点
- 35例肝细胞癌患者共42次90Y树脂微球放射性栓塞治疗,采用体表面积模型规划注射活度。
- 26次治疗可评估6个月疗效,客观缓解14次、无缓解12次。
- 客观缓解者的平均剂量及剂量体积直方图指标显著高于无缓解者。
核心结论
- 在本研究人群中,肿瘤平均吸收剂量和剂量体积直方图指标与肿瘤缓解相关。
- 体表面积方法计算的活度可增加以达到推荐的肿瘤剂量阈值。
- 活度规划应考虑肿瘤摄取、靶区与非靶区体积以及剂量分布异质性。
研究设计与样本
- 回顾性体素剂量学研究,纳入35例肝细胞癌患者共42次90Y树脂微球放射性栓塞治疗。
- 注射活度按体表面积模型规划,基于99mTc标记大颗粒聚合白蛋白SPECT和90Y微球PET使用专用治疗计划系统回顾性行体素剂量学分析。
- 分析解剖定义肿瘤的平均剂量和剂量体积直方图,提取最小剂量覆盖50%和70%肿瘤体积及接受至少120 Gy的体积百分比作为剂量指标。
- 治疗后6个月按欧洲肝病研究协会标准评估疗效。
主要发现
- 26次治疗可评估6个月疗效,其中14次为客观缓解、12次为无缓解。
- 基于90Y微球PET的回顾性剂量学显示患者间变异大,肿瘤中位平均吸收剂量为60 Gy。
- 62%(26/42)的病例中,若增加体表面积方法计算的注射活度,肿瘤、非肿瘤肝和肺剂量本可符合推荐阈值。
- 客观缓解者的平均剂量、最小剂量覆盖50%和70%肿瘤体积及接受至少120 Gy的体积百分比均显著高于无缓解者。
关键数值与推荐
- 疗效评估采用欧洲肝病研究协会标准,于治疗后6个月进行。
- 剂量体积直方图提取的剂量指标为最小剂量覆盖50%和70%肿瘤体积及接受至少120 Gy的体积百分比。
- 62%(26/42)的病例在增加体表面积方法计算的注射活度后,肿瘤、非肿瘤肝和肺剂量本可符合推荐阈值。
临床怎么用
- 原文结论未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this study was to quantitatively evaluate the ability of the body-surface-area (BSA) model to predict tumor-absorbed dose and treatment outcome through retrospective voxel-based dosimetry. Methods: Data from 35 hepatocellular carcinoma patients with a total of 42 90Y-resin microsphere radioembolization treatments were included. Injected activity was planned with the BSA model. Voxel dosimetry based on 99mTc-labeled macroaggregated albumin SPECT and 90Y-microsphere PET was retrospectively performed using a dedicated treatment planning system. Average dose and dose-volume histograms (DVHs) of the anatomically defined tumors were analyzed. The selected dose metrics extracted from DVHs were minimum dose to 50% and 70% of the tumor volume and percentage of the volume receiving at least 120 Gy. Treatment response was evaluated 6 mo after therapy according to the criteria of the European Association for the Study of the Liver. Results: Six-month response was evaluated in 26 treatments: 14 were considered to produce an objective response and 12 a nonresponse. Retrospective evaluation of 90Y-microsphere PET-based dosimetry showed a large interpatient variability with a median average absorbed dose of 60 Gy to the tumor. In 62% (26/42) of the cases, tumor, nontumoral liver, and lung doses would have complied with the recommended thresholds if the injected activity calculated by the BSA method had been increased. Average doses, minimum dose to 50% and 70% of the tumor volume, and percentage of the volume receiving at least 120 Gy were significantly higher in cases of objective response than in nonresponse. Conclusion: In our population, average tumor-absorbed dose and DVH metrics were associated with tumor response. However, the activity calculated by the BSA method could have been increased to reach the recommended tumor dose threshold. Tumor uptake, target and nontarget volumes, and dose distribution heterogeneity should be considered for activity planning.
引用
- Kafrouni M, Allimant C, Fourcade M, et al. Retrospective Voxel-Based Dosimetry for Assessing the Ability of the Body-Surface-Area Model to Predict Delivered Dose and Radioembolization Outcome. J Nucl Med. 2018. PMID: 29545380. doi:10.2967/jnumed.117.202937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。